Philip Scheltens

Philip Scheltens is a Partner and Head of the Dementia Fund at EQT Life Sciences, currently based in Amsterdam, Netherlands. Before transitioning to the venture capital sector, he served as a Professor of Neurology at Amsterdam University Medical Centers and directed the Alzheimer Center Amsterdam from 2000 to 2021. He initially joined the firm Life Sciences Partners in 2021 before its acquisition by EQT, where he now oversees a EUR 273 million fund that has invested in nine companies, including the biotechnology firm New Amsterdam Pharma. Throughout his extensive clinical and academic career, Scheltens acted as the principal investigator for over 35 clinical trials, supervised more than 100 PhD theses, and authored over 1,100 peer-reviewed papers. His current professional focus centers on financing early-stage therapeutics, biomarker diagnostics, and clinical trials targeting Alzheimer's disease and broader neurodegenerative conditions.